Caption Management, LLC Vertex Pharmaceuticals Inc Put Options Transaction History

Caption Management, LLC

10 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2024 May 15, 2024	BUY	$407.69 - $446.08 $5.71 Million - $6.25 Million	14,000 New	14,000 $5.85 Million
Q3 2023 Nov 14, 2023	BUY	$338.18 - $362.46 $5.07 Million - $5.44 Million	15,000 New	15,000 $5.22 Million
Q2 2022 Aug 15, 2022	SELL	$234.96 - $292.55 $49.3 Million - $61.4 Million	-209,900 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$221.42 - $260.97 $35.4 Million - $41.7 Million	159,900 Added 319.8%	209,900 $54.8 Million
Q4 2021 Feb 11, 2022	SELL	$177.01 - $223.45 $2.66 Million - $3.35 Million	-15,000 Reduced 23.08%	50,000 $11 Million
Q3 2021 Nov 12, 2021	BUY	$181.39 - $202.99 $11.8 Million - $13.2 Million	65,000 New	65,000 $11.8 Million
Q2 2020 Aug 14, 2020	SELL	$225.48 - $295.8 $6.18 Million - $8.1 Million	-27,400 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$199.77 - $247.81 $5.47 Million - $6.79 Million	27,400 New	27,400 $6.52 Million
Q3 2019 Nov 14, 2019	SELL	$166.23 - $187.09 $4.16 Million - $4.68 Million	-25,000 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$163.73 - $194.7 $4.09 Million - $4.87 Million	25,000 New	25,000 $4.6 Million

1,723

222M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $116B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Caption Management, LLC with notifications on news.